Will mRNA Technology Companies Spawn Innovation Ecosystems?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning
Standard
Will mRNA Technology Companies Spawn Innovation Ecosystems? / Grimpe, Christoph; Minssen, Timo; Price II, William Nicholson; Stern, Ariel.
I: Harvard Business Review, 18.04.2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Will mRNA Technology Companies Spawn Innovation Ecosystems?
AU - Grimpe, Christoph
AU - Minssen, Timo
AU - Price II, William Nicholson
AU - Stern, Ariel
PY - 2022/4/18
Y1 - 2022/4/18
N2 - The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.
AB - The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.
KW - Faculty of Law
KW - platform economy
KW - management
KW - Vaccines
KW - regulation
KW - Intellectual property
KW - Open innovation
KW - collaboration
M3 - Journal article
JO - Harvard Business Review
JF - Harvard Business Review
SN - 0017-8012
ER -
ID: 279498395